IBRX
Price
$2.87
Change
+$0.08 (+2.87%)
Updated
Jul 10, 04:59 PM (EDT)
Capitalization
2.46B
27 days until earnings call
MDGL
Price
$310.00
Change
+$1.41 (+0.46%)
Updated
Jul 10, 12:49 PM (EDT)
Capitalization
6.85B
27 days until earnings call
Interact to see
Advertisement

IBRX vs MDGL

Header iconIBRX vs MDGL Comparison
Open Charts IBRX vs MDGLBanner chart's image
ImmunityBio
Price$2.87
Change+$0.08 (+2.87%)
Volume$167.26K
Capitalization2.46B
Madrigal Pharmaceuticals
Price$310.00
Change+$1.41 (+0.46%)
Volume$100
Capitalization6.85B
IBRX vs MDGL Comparison Chart in %
Loading...
IBRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IBRX vs. MDGL commentary
Jul 10, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IBRX is a StrongBuy and MDGL is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 10, 2025
Stock price -- (IBRX: $2.79 vs. MDGL: $308.59)
Brand notoriety: IBRX and MDGL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IBRX: 76% vs. MDGL: 119%
Market capitalization -- IBRX: $2.46B vs. MDGL: $6.85B
IBRX [@Biotechnology] is valued at $2.46B. MDGL’s [@Biotechnology] market capitalization is $6.85B. The market cap for tickers in the [@Biotechnology] industry ranges from $314.48B to $0. The average market capitalization across the [@Biotechnology] industry is $2.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IBRX’s FA Score shows that 1 FA rating(s) are green whileMDGL’s FA Score has 0 green FA rating(s).

  • IBRX’s FA Score: 1 green, 4 red.
  • MDGL’s FA Score: 0 green, 5 red.
According to our system of comparison, MDGL is a better buy in the long-term than IBRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IBRX’s TA Score shows that 5 TA indicator(s) are bullish while MDGL’s TA Score has 6 bullish TA indicator(s).

  • IBRX’s TA Score: 5 bullish, 4 bearish.
  • MDGL’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, MDGL is a better buy in the short-term than IBRX.

Price Growth

IBRX (@Biotechnology) experienced а +5.68% price change this week, while MDGL (@Biotechnology) price change was +2.81% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.89%. For the same industry, the average monthly price growth was +16.25%, and the average quarterly price growth was +20.89%.

Reported Earning Dates

IBRX is expected to report earnings on Nov 07, 2025.

MDGL is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+9.89% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDGL($6.85B) has a higher market cap than IBRX($2.46B). IBRX YTD gains are higher at: 8.984 vs. MDGL (0.006). IBRX has higher annual earnings (EBITDA): -264M vs. MDGL (-376.15M). MDGL has more cash in the bank: 843M vs. IBRX (61.6M). MDGL has less debt than IBRX: MDGL (120M) vs IBRX (526M). MDGL has higher revenues than IBRX: MDGL (317M) vs IBRX (31.2M).
IBRXMDGLIBRX / MDGL
Capitalization2.46B6.85B36%
EBITDA-264M-376.15M70%
Gain YTD8.9840.006138,692%
P/E RatioN/AN/A-
Revenue31.2M317M10%
Total Cash61.6M843M7%
Total Debt526M120M438%
FUNDAMENTALS RATINGS
IBRX vs MDGL: Fundamental Ratings
IBRX
MDGL
OUTLOOK RATING
1..100
6272
VALUATION
overvalued / fair valued / undervalued
1..100
4
Undervalued
64
Fair valued
PROFIT vs RISK RATING
1..100
10039
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
6461
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IBRX's Valuation (4) in the Biotechnology industry is somewhat better than the same rating for MDGL (64) in the Pharmaceuticals Other industry. This means that IBRX’s stock grew somewhat faster than MDGL’s over the last 12 months.

MDGL's Profit vs Risk Rating (39) in the Pharmaceuticals Other industry is somewhat better than the same rating for IBRX (100) in the Biotechnology industry. This means that MDGL’s stock grew somewhat faster than IBRX’s over the last 12 months.

MDGL's SMR Rating (97) in the Pharmaceuticals Other industry is in the same range as IBRX (100) in the Biotechnology industry. This means that MDGL’s stock grew similarly to IBRX’s over the last 12 months.

MDGL's Price Growth Rating (61) in the Pharmaceuticals Other industry is in the same range as IBRX (64) in the Biotechnology industry. This means that MDGL’s stock grew similarly to IBRX’s over the last 12 months.

MDGL's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as IBRX (100) in the Biotechnology industry. This means that MDGL’s stock grew similarly to IBRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IBRXMDGL
RSI
ODDS (%)
Bearish Trend 2 days ago
70%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
86%
Momentum
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
78%
MACD
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 4 days ago
78%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
76%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 8 days ago
84%
Bullish Trend 11 days ago
77%
Declines
ODDS (%)
Bearish Trend 10 days ago
90%
Bearish Trend 3 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
89%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
IBRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RMFAX59.150.27
+0.46%
American Funds American Mutual R1
EAERX22.34N/A
N/A
Eaton Vance Stock A
PRDMX50.28N/A
N/A
T. Rowe Price Diversified Mid Cap Gr
MAVKX14.18N/A
N/A
MoA Small Cap Value Fund
MEMSX8.71N/A
N/A
Mercer Emerging Markets Equity I

IBRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, IBRX has been loosely correlated with AXON. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if IBRX jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IBRX
1D Price
Change %
IBRX100%
+2.95%
AXON - IBRX
48%
Loosely correlated
+1.98%
RXRX - IBRX
42%
Loosely correlated
+4.29%
ARRY - IBRX
41%
Loosely correlated
+4.62%
CLRB - IBRX
41%
Loosely correlated
+3.19%
QTTB - IBRX
39%
Loosely correlated
+8.63%
More